US Affiliate of GC Cell
On Aug. 17, GC Cell announced that its U.S. affiliate, Artiva Biotherapeutics, has received approval from the U.S. FDA for the Investigational New Drug application of its AB-101 natural killer (NK) cell therapy for lupus nephritis.
Lupus is an autoimmune disease caused by immune system abnormalities leading to inflammation throughout the body and potential organ damage. The company explained that 40% of patients with this condition suffer from lupus nephritis.
AB-101 is an allogeneic NK cell therapy derived from umbilical cord blood, a technology developed by GC Cell and transferred to Artiva. Currently, Phase 1 and 2 clinical trials are underway in the U.S. targeting patients with recurrent and refractory B-cell non-Hodgkin lymphoma, combined with rituximab.
James Park, the representative of GC Cell, said, “NK cell therapies are expanding their horizons from oncology to autoimmune diseases. GC Cell plans to closely cooperate with Artiva and extend developments in the Asia-Pacific region depending on Artiva’s development progress.”